Assess whether biosimilarity is analytically justified (e81fbc)

Situation

A mid-size sponsor after a complete response letter cannot treat a pediatric ethicist objecting to the proposed design as color commentary on scientific-advice briefing book. Pharmacovigilance medical reviewer must close biosimilarity is analytically justified from that extract under Pharma & Life Sciences / CMC and Development Pathways.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Authorize Proceed under protocol now; scientific-advice briefing book already has the discriminator after a pediatric ethicist objecting to the proposed design.
• Keep Pause the pathway in force until scientific-advice briefing book is completed after a pediatric ethicist objecting to the proposed design for pharmacovigilance medical reviewer.
• Treat scientific-advice briefing book as Escalate safety review because both readings appear after a pediatric ethicist objecting to the proposed design.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page biosimilarity is analytically justified turns on in scientific-advice briefing book.

Analysis required

• Check whether scientific-advice briefing book supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a pediatric ethicist objecting to the proposed design and write the one fact that would move biosimilarity is analytically justified for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.